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beekeepers or subjects with a bee-house in the vicinity suf-
fered a bee re-sting within 5.25 years compared to 10.75 
years for individuals who were not beekeepers.  Conclu-
sions: The high degree of exposure of vespid-venom-aller-
gic outdoor workers and bee-venom-allergic beekeepers 
and subjects living close to bee-houses underlines the high 
benefit of venom immunotherapy for these patients even if 
they suffered a non-life-threatening grade II reaction. Yet, 
bee-venom-allergic individuals with no proximity to bee-
houses and with an indoor occupation face a very low expo-
sure risk, which justifies epinephrine rescue treatment for 
these patients especially if they have suffered from grade II 
sting reactions.  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Hymenoptera venom allergy is a potentially life-
threatening condition. The reported prevalence of sys-
temic allergic reactions is 0.3–7.5% in Europe  [1] . The 
emergency treatment comprises the administration of 
antihistamines, oral corticosteroids and, in the case of 
moderate to severe anaphylactic reactions, intramuscular 
injection of epinephrine  [2–4] . The only disease-modify-
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 Abstract 
 Background: Venom immunotherapy is highly efficacious 
in preventing anaphylactic sting reactions. However, there 
is an ongoing discussion regarding patient selection and 
whether and how to apply a cost-benefit analysis of venom 
immunotherapy. In order to help decision-making, we inves-
tigated the re-sting frequency of hymenoptera-venom-al-
lergic patients to single out those at high risk.  Methods: In 
this retrospective study, re-sting data of 96 bee-venom-aller-
gic patients and 95 vespid-venom-allergic patients living 
mainly in a rural area of Switzerland were analyzed. Hyme-
noptera venom allergy status was rated according to the 
classification system of H.L. Mueller [J Asthma Res 1966;3:331–
333]. Different risk-groups were defined according to sting 
exposure and their median sting-free interval was calculat-
ed.  Results: The risk factors for a wasp or bee re-sting were 
outdoor occupation, beekeeping and habitation close to a 
bee-house. Half of all vespid-venom-allergic outdoor work-
ers were re-stung within 3.75 years compared to 7.5 years for 
indoor workers. Similarly, 50% of the bee-venom-allergic 
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ing treatment option is venom immunotherapy (VIT) 
with an established efficacy of 95% in vespid-venom-al-
lergic and 75–85% in bee-venom-allergic patients  [2, 3, 5, 
6] . VIT has also been shown to improve the health-relat-
ed quality of life of the patients  [7–8] . Although highly 
efficacious, VIT requires injections every 4–8 weeks over 
3–5 years  [2, 3, 9] , and is associated with a risk of treat-
ment-associated allergic side effects in up to 20% of all 
patients  [10] which impedes treatment compliance  [11, 
12] . Furthermore, prediction of the future course of hy-
menoptera venom allergy (i.e. prediction of the reaction 
to a re-sting) is difficult, keeping the discussion about 
patient selection for VIT ongoing  [13, 14] .
 There are indeed regional differences in the recom-
mendations to initiate VIT. In the USA, VIT is recom-
mended for all adult patients who have experienced a sys-
temic reaction  [2] . European guidelines recommend VIT 
for patients with a history of severe life-threatening 
grade-III or grade IV systemic allergic sting reactions ac-
cording to H.L. Mueller ( table 1 )  [15, 16] , including respi-
ratory or cardiovascular symptoms  [3] . Such recommen-
dation is based on the observation that patients with an 
initial grade III or grade IV reaction face a 30–60% risk 
of suffering a life-threatening systemic reaction upon a 
re-sting, if untreated  [17, 18] . However, there is a grey zone 
concerning patients with a grade I or grade II systemic 
reaction. For such patients, who have suffered a non-life-
threatening grade I or grade II reaction, (i) other factors 
 associated with a high risk of suffering a severe reaction 
upon a re-sting ( table 2 ), (ii) high sting exposure or (iii) 
highly impaired quality of life also justify initiation of 
VIT  [3] . While the former issue has been extensively in-
vestigated, data regarding exposure risk is poor. Occupa-
tion, leisure activity, residence, age and sex have been de-
scribed as influencing the exposure risk  [9, 18–22] . Fur-
thermore, a personal history of an anaphylactic sting 
reaction also affects exposure risk as the fear of a future 
allergic reaction induces behavioral changes associated 
with avoidance measures  [8] . Moreover, patient educa-
tion including preventive measures has the potential to 
minimize the re-sting risk  [3] . Yet, the actual sting fre-
quency in allergic patients has never been quantified so 
far. However, this parameter might help to evaluate the 
benefit for individual patients of undergoing VIT.
 This study therefore investigated and quantified the 
sting frequency in hymenoptera-venom-allergic patients 
in order to define high and low sting-exposure groups 
and to help decision-making with regard to VIT initia-
tion, particularly in grey-zone situations concerning pa-
tients with grade I and grade II allergic reactions.
 Material and Methods 
 Study Design and Patient Selection 
 This study was designed as a retrospective observational 
study. Patients were recruited from an allergologist’s practice in a 
Swiss town, Lucerne (76,000 inhabitants), with a large rural ag-
glomeration (274,000 inhabitants). Patients with a severe system-
ic allergic sting reaction or a high level of fear due to the allergic 
sting reaction were treated with VIT. Hence, hymenoptera venom 
allergy status was rated between Mueller grade III and grade IV 
in 95% of the patients. Patients who started ultrarush VIT be-
tween the years 1996 and 2003 were included and followed up 
until the end of 2008 in order to obtain data regarding hymenop-
tera stings. With the exception of beekeepers who were instructed 
to wear protective clothing with nets and gloves, patients did not 
get specific recommendations on how to prevent future hyme-
noptera stings. Patients who were lost to follow-up were not in-
Table 1. C lassification of allergic reactions modified according to 
H.L. Mueller [15]
Large local
reaction
swelling at site of sting with diameter >10 
cm, lasting >24 h
Systemic reaction
grade I
generalized urticaria, itching, malaise and 
anxiety
Systemic reaction
grade II
any of the above, plus 2 or more of the fol-
lowing: angioedema, constriction in the 
chest, nausea, vomiting, diarrhea, abdom-
inal pain and dizziness
Systemic reaction
grade III
any of the above, plus 2 or more of the fol-
lowing: dyspnoea, wheezing, stridor, dys-
phagia, dysarthria, hoarseness, weakness, 
confusion and fear of death
Systemic reaction
grade IV
any of the above plus 2 or more of the fol-
lowing: a drop in blood pressure, collapse, 
loss of consciousness, incontinence (urine 
or stools), cyanosis
Table 2.  Risk factors for a severe reaction to a hymenoptera sting 
[18, 19, 22, 25, 26]
History of a prior severe sting reaction
(with respiratory or cardiovascular symptoms)
Vespid venom allergy (for field stings)
Time interval between stings (<5 years)
Elevated serum tryptase, mastocytosis
Preexisting diseases (e.g. cardiovascular or asthma)
Drugs (e.g. beta-blocker and angiotensin-converting enzyme 
inhibitors)
Older age
Male sex
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cluded in the respective analyses. A total of 106 bee-venom-aller-
gic patients and 108 vespid-venom-allergic patients undergoing 
VIT were enrolled, and the re-sting data of 96 bee-venom-allergic 
patients and 95 vespid-venom-allergic patients could be analyzed. 
The median follow-up period was 6.6 years.
 The study was performed with the approval of the local ethics 
review committee.
 Re-Sting Data Collection 
 The demographic data, data on the patients’ medical history 
and the results of any hymenoptera-specific diagnostic tests were 
collected from the medical records. Details on hymenoptera 
stings during therapy were obtained at follow-up visits 3 or 5 years 
after the start of VIT. Patients were sent a questionnaire to assess 
the sting frequency after therapy discontinuation. Patients who 
did not return the questionnaire were contacted by phone.
 Statistical Analysis 
 The evaluation of the risk of suffering a sting was calculated 
with a multivariate logistic regression analysis. The final model 
included variables from  table 3 , if p  ! 0.1 as well as the factor ‘time 
of observation’, for which the outcome variable was controlled. 
Unfortunately, with only 4 beekeepers in our sample, we could not 
run a logistic regression analysis with beekeeping as a risk factor, 
instead merging them with the group of patients living close to a 
bee-house.
 For calculation of the time interval from the start of VIT to the 
first re-sting, a Kaplan-Meier survival analysis was performed 
with a log-rank test.
 Results 
 A total of 96 bee-venom-allergic patients and 95 ves-
pid-venom-allergic patients with re-sting data could be 
analyzed. Male sex was overrepresented in both groups. 
Three quarters of the patients were living in a rural envi-
ronment. The mean age at the start of VIT was 30.6 years 
for bee-venom-allergic patients and 36.1 years for vespid-
venom-allergic patients, respectively ( table 3 ).
 Risk Factors for Re-Sting 
 The logistic regression analysis revealed that working 
outdoors, being a child or having a bee-house in the vi-
cinity represented a 2–3 times higher risk for bee-venom-
allergic patients to be re-stung ( table 4 ). In the multivari-
ate regression analysis, the significance level of 0.05, how-
ever, could not always be met ( table 5 ). It must be noted 
that the group of beekeepers was merged with patients 
living near a bee-house. It is obvious that beekeepers face 
a much higher risk of being re-stung; all 4 reported to 
have received more than 30 stings.
 Vespid-venom-allergic patients with an outdoor occu-
pation were found to have a 5 times higher risk of suffer-
ing a re-sting than those with an indoor occupation ( ta-
bles 6 ,  7 ). Sex, age, residency and leisure activity were not 
associated with a higher sting risk ( tables 4 ,  6 ).
 Sting-Free Time 
 A Kaplan-Meier analysis revealed a median sting-free 
interval of 7.75 years (93 months, 95% CI 58.34–127.67) 
for the patients with bee-venom-allergy and a median 
sting-free interval of 5.52 years (65 months, 95% CI 55.91–
74.09) for patients with vespid-venom-allergy. Sting-free 
time was significantly different according to occupation 
for vespid-venom-allergic patients (p  ! 0.001) and ac-
cording to the presence of a bee-house in the vicinity for 
bee-venom-allergic patients (p = 0.019) ( fig. 1 ,  2 ). A log-
rank test was not calculated to investigate the association 
between occupation and sting-free time for bee-sting-al-
lergic patients as the proportional hazards assumption 
was not met.
 Stratifying the data according to the factor bee-house 
in the vicinity for bee-venom-allergy resulted in median 
sting-free intervals of 5.25 years (63 months, 95% CI 
54.9–71.1) for people with a bee-house in the vicinity and 
10.75 years (129 months, 95% CI 85.8–172.2) for people 
not living near one. Stratification for occupation revealed 
a median re-sting-free interval of 6.66 (116 months) years 
for outdoor workers and 9.66 years (80 months, 95% CI 
62.5–97.5) for indoor workers ( table 8 ).
Table 3.  Baseline characteristics of study population
Characteristics S tudy population
bee-venom-
allergic
( n = 96)
vespid-venom-
allergic
(n = 95)
Re-stung 45 (46.9%) 50 (52.6%)
Mean age 8 SD, years 30.6817.3 36.1817.3
Male
Female
63 (65.6%)
33 (34.4%)
53 (55.8%)
42 (44.2%)
Residency
Rural area
Town/agglomeration
79 (82.3%)
17 (17.7%)
63 (66.3%)
32 (33.7%)
Occupation
Indoor work
Outdoor work
Children
46 (47.9%)
25 (26.0%)
25 (26.0%)
55 (57.9%)
27 (28.4%)
13 (13.7%)
Beekeeping not applicable
Beekeeper
Bee-house in the vicinity
No relation to beekeeping
4 (4.2%)
35 (36.5%)
57 (59.4%)
Leisure activity
Outdoor hobby
No outdoor hobby
65 (67.7%)
31 (32.3%)
53 (55.8%)
42 (44.2%)
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Table 4.  Univariate logistic regression analysis for risk of a bee re-sting
Variable Total (%) Crude OR 95% CI p value
Age 96 (100) 0.988 0.965–1.011 0.303
Sex
Male
Female
63 (65.6)
33 (34.4)
0.625
1
0.268–1.459 0.277
Residency
Town/agglomeration
Rural area
17 (17.7)
79 (82.3)
0.406
1
0.131–1.261 0.119
Leisure activity
No outdoor hobby
Outdoor hobby
31 (32.3)
65 (67.7)
1.324
1
0.562–3.121 0.521
Occupation
Outdoor work
Children
Indoor work
25 (26.0)
25 (26.0)
46 (47.9)
2.386
2.812
1
0.882–6.460
1.030–7.677
0.087
0.044
Beekeeping
Beekeeper/bee-house nearby
No relation to a bee-house
39 (40.6)
57 (59.4)
2.287
1
0.996–5.253 0.051
Time of observation 93 (100) 1.294 0.996–1.680 0.053
Table 5. Multivariate logistic regression analysis for risk of a bee re-sting
Variable Total (%) Adjusted OR 95% CI p value
Occupation
Outdoor work
Children
Indoor work
24 (25.8)
25 (26.9)
44 (47.3)
2.431
2.992
1
0.833–7.095
1.032–8.675
0.104
0.044
Beekeeping
Beekeeper/bee-house nearby
No relation to a bee-house
38 (40.9)
55 (59.1)
2.147
1
0.878–5.247 0.094
Time of observation 93 (100) 1.288 0.975–1.702 0.075
Table 6.  Univariate logistic regression analysis for risk of a wasp re-sting
Variable Total (%) Crude OR 95% CI p value
Age 95 (100) 0.992 0.969–1.015 0.495
Sex
Male
Female
53 (55.8)
42 (44.2)
1.208
1
0.537–2.720 0.648
Residency
Town/agglomeration
Rural area
32 (33.7)
63 (66.3)
1.030
1
0.439–2.416 0.945
Leisure activity
No outdoor hobby
Outdoor hobby
42 (44.2)
53 (55.8)
1.166
1
0.518–2.625 0.711
Occupation
Outdoor work
Children
Indoor work
27 (28.4)
13 (13.7)
55 (57.9)
5.250
1.750
1
1.827–15.086
0.518–5.907
0.002
0.367
Time of observation 94 (100) 0.908 0.654–1.260 0.564
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 For vespid-venom-allergy, stratification according to 
occupation revealed median re-sting-free intervals of 
3.75 years (45 months, 95% CI 34.8–55.2) for outdoor 
workers and 7.5 years (90 months, 95% CI 70.8–109.2) for 
indoor workers ( table 8 ).
 Discussion 
 Venom immunotherapy is the only disease modifying 
treatment option for hymenoptera venom allergy show-
ing a high success rate. However, a long treatment dura-
tion requiring injections every 4–8 weeks over 3–5 years 
associated with high treatment costs, and the risk of 
treatment-associated allergic side effects keeps the dis-
cussion on whom to select for VIT ongoing. We focused 
on the determination of the sting frequency of different 
hymenoptera-venom-allergic patients in order to help de-
cision-making, especially with regard to patients suffer-
ing from mild systemic sting reactions.
 Analyzing data from Swiss hymenoptera-venom-al-
lergic patients living to a large extent in a rural environ-
ment, we found outdoor occupation to be the only risk 
factor for a wasp re-sting whereas outdoor occupation, 
beekeeping or living in the vicinity of a bee-house are all 
risk factors for a bee re-sting. Being a child also seemed 
to be associated with a higher risk of a bee re-sting, but 
not for a wasp re-sting.There was, however, no difference 
in the risk of re-stings between children living in the vi-
Table 7.  Multivariate logistic regression analysis for risk of a wasp 
re-sting
Variable Total (%) Adjusted
OR
95% CI p
value
Occupation
Outdoor work
Children
Indoor work
27 (28.7)
12 (12.8)
55 (58.5)
5.187
1.501
1
1.798–14.961
0.428–5.261
0.002
0.526
Time of observation 94 (100) 0.956 0.677–1.352 0.800
Table 8.  Median sting-free time for bee-venom-allergic and ves-
pid-venom-allergic subjects according to whether or not they have 
a bee-house in their vicinity and their occupation
Estimate
months
Lower
95% CI
Upper
95% CI
Bee venom
Bee-house in vicinity
Yes 63.0 54.9 71.1
No 129.0 85.8 172.2
Occupation
Outdoor work 80.0 62.5 97.5
Children 70.0 31.8 108.2
Indoor work 116.0 – –
Wasp venom
Occupation
Outdoor work 45.0 34.8 55.2
Children 60.0 54.8 65.2
Indoor work 90.0 70.8 109.2
 Fig. 1. Kaplan-Meier analysis for bee-venom-allergic patients 
showing the cumulative percentage of re-stings for beekeepers/
subjects in the vicinity of a bee-house compared to subjects who 
were not beekeepers (p = 0.019). 
 Fig. 2. Kaplan-Meier analysis for vespid-venom-allergic patients 
showing the cumulative percentage of re-stings for indoor work-
ers compared to outdoor workers and children (p  ! 0.001). 
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cinity of a bee-house and children living nowhere near 
one. While this result is difficult to explain, we do not 
want to overstate its importance, particularly as its statis-
tical significance is only moderate. Beyond that, our 
study shows that 50% of the patients belonging to a high-
risk group were re-stung within 3.75 to 5.25 years on av-
erage. In contrast, 50% of vespid-venom-allergic indoor 
workers and bee-venom-allergic subjects other than the 
beekeepers working indoors experienced periods of 7.5 
and 10.75 years respectively without suffering a wasp or 
bee re-sting, respectively. These figures have to be inter-
preted cautiously, however, as we cannot be completely 
sure that patients recalled correctly when they had been 
re-stung.
 For a long time, beekeepers and their family members 
have been identified as a high-risk group of hymenoptera-
venom-allergic patients, and management options for 
this population have already been adapted, recommend-
ing VIT not only to beekeepers suffering from mild grade 
I and grade II systemic allergic reactions, but even to 
those suffering from repeated large local reactions  [23] . 
However, the majority (63%) of bee-venom-allergic pa-
tients do not belong to this high-risk group and only face 
a small risk of being re-stung. For the bee-venom-allergic 
patients – other than the beekeepers, with no vicinity to 
a bee-house and with an indoor occupation – who only 
suffered a non-life-threatening grade I or grade II sting 
reaction in the absence of other risk factors (see  table 2 ), 
the benefit of a time-consuming and risk-associated VIT 
is small and prescription of autoinjectable epinephrine as 
a rescue treatment is justified. Indeed, young patients es-
pecially have been shown to prefer this to VIT  [24] .
 With regard to vespid-venom-allergic patients, the im-
pact of our study mainly concerns vespid-venom-allergic 
outdoor workers with mild systemic reactions, who suffer 
a high degree of exposure. It has been demonstrated that 
hymenoptera re-stings within a time interval of 2 weeks 
to 5 years comprise a 40–77% risk of inducing a more se-
vere reaction  [18] . Combined with our data, these obser-
vations allow the conclusion that vespid-venom-allergic 
outdoor workers with a grade II systemic reaction face a 
considerable risk of suffering a future grade III reaction 
when re-stung. Prescription of VIT is therefore highly 
recommended after grade II systemic reactions for these 
individuals. Contrarily, re-sting risk for vespid-venom-
allergic indoor workers is small, reducing benefit of VIT 
after mild systemic sting reaction for this patient group.
 Even though hymenoptera venom allergy has been 
studied extensively, the actual sting frequency has never 
been thoroughly investigated. It has been described that 
climate, temperature and certain occupations and activi-
ties (such as beekeeping) influence the risk of being re-
stung  [19] , but this risk has never been quantified. Based 
on the analysis of a Swiss population living mainly in a 
rural environment, we substantiated the high sting fre-
quency not only of beekeepers and their family members, 
but also of vespid-venom-allergic outdoor workers. On 
the other hand, both bee-venom-allergic patients in no 
proximity to a bee-house and with an indoor occupation 
as well as vespid-venom-allergic subjects who work in-
doors face a very low sting exposure risk. This informa-
tion may affect the decision-making process in VIT situ-
ations concerning patients with grade I and grade II sys-
temic allergic reactions where the cost benefits of VIT 
come into question.
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